English
Тестостерон-заместительная терапия при мужском гипогонадизме: взгляд из 21 века
DOI: https://dx.doi.org/10.18565/urology.2025.1.93-103
Раснер П.И., Рева И.А., Карамышева Е.И., Алиев Р.И.
Научно-образовательный институт клинической медицины им. Н.А. Семашко ФГБОУ ВО «Российский университет медицины» (директор – д.м.н., профессор А.А. Солодов), Москва, Россия
Настоящая работа посвящена анализу эффективности тестостерон-заместительной терапии в лечении основных симптомов постпубертатного гипогонадизма, ее влиянию на сопутствующие соматические заболевания, безопасности и разумному выбору лекарственной формы препарата тестостерона.
Литература
1) Salonia A., Rastrelli G., Hackett G. et al. Paediatric and adult-onset male hypogonadism. Nat Rev Dis Primers. 2019;30;5(1):38. DOI: 10.1038/s41572-019-0087-y.
2) Nieschlag E., Behre M.H., Nieschlag S. Andrology: male reproductive health and dysfunction. 3rd edn., Springer Science & Business Media, 2010, 629 p.
3) European Association of Urology Guidelines on Sexual and Reproductive Health 2024. https://uroweb.org/guidelines/sexual-and-reproductive-health
4) Corona G., Giagulli V.A., Maseroli E. et al. THERAPY OF ENDOCRINE DISEASE: Testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. 2016;174: R99. DOI: 10.1530/EJE-15-0262.
5) Corona G., Rastrelli G., Morgentaler A. et al. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores. Eur Urol. 2017;72(6):1000-1011. DOI: 10.1016/j.eururo.2017.03.032.
6) Bettocchi C. Late-Onset Hypogonadism (LOH): Incidence, Diagnosis, and Short-Term Effects. European Urology Supplements, 2005;(4):6:4-9. DOI: 10.1016/j.eursup.2005.05.002.
7) Feldman H.A., Longcope C., Derby C.A. et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal resultsfrom the Massachusetts male aging study. 2002;87(2):589-98. DOI: 10.1210/jcem.87.2.8201.
8) Dimopoulou C., Ceausu I., Depypere H. et al. EMAS position statement: Testosterone replacement therapy in the aging male. Maturitas. 2016;84:94-9. DOI: 10.1016/j.maturitas.2015.11.003.
9) Haring R., Völzke H., Steveling A. et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J. 2010;31: 1494. DOI: 10.1093/eurheartj/ehq009.
10) Zarotsky V., Huang M.Y., Carman W. et al. Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. Andrology. 2014;2(6):819-34. DOI: 10.1111/andr.274.
11) Huo S., Scialli A.R., McGarvey S. et al. Treatment of Men for «Low Testosterone»: A Systematic Review. PLoS One, 2016;11(9):e0162480. DOI: 10.1371/journal.pone.0162480.
12) Rastrelli G., Guaraldi F., Reismann Y. et al. Testosterone Replacement Therapy for Sexual Symptoms. 2019;7(3):464-475. DOI: 10.1016/j.sxmr.2018.11.005.
13) Lee H., Hwang E.C., Oh C.K. et al. Testosterone replacement in men with sexual dysfunction. Cochrane Database Syst Rev. 2024;1(1):CD013071. DOI: 10.1002/14651858.CD013071.pub2.
14) Snyder P.J., Bhasin S., Cunningham G.R. et al. Lessons From the Testosterone Trials. Endocr Rev. 2018;39(3):369-386. DOI: 10.1210/er.2017-00234.
15) Cunningham G.R., Stephens-Shields A.J., Rosen R.C. et al. Association of sex hormones with sexual function, vitality, and physical function of symptomatic older men with low testosterone levels at baseline in the testosterone trials. J Clin Endocrinol Metab. 2015;100(3):1146-55. DOI: 10.1210/jc.2014-3818.
16) Corona G., Rastrelli G., Morgentaler A. et al. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores. Eur Urol. 2017;72(6):1000-1011. DOI: 10.1016/j.eururo.2017.03.032.
17) Corona G., Rastrelli G., Vignozzi L. et al. Androgens and male sexual function. Best Pract Res Clin Endocrinol Metab. 2022;36(4):101615. DOI: 10.1016/j.beem.2022.101615.
18) Pencina K.M., Travison T.G., Cunningham G.R. et al. Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. J Clin Endocrinol Metab. 2024;109(2):569-580. DOI: 10.1210/clinem/dgad484. PMID: 37589949.
19) Chamness S.L., Ricker D.D., Crone J.K. et al. The effect of androgen on nitric oxide synthase in the male reproductive tract of the rat. Fertil Steril. 1995;63(5):1101-7.
20) Schirar A., Bonnefond C., Meusnier C., Devinoy E. Androgens modulate nitric oxide synthase messenger ribonucleic acid expression in neurons of the major pelvic ganglion in the rat. Endocrinology. 1997;138(8):3093-102. DOI: 10.1210/endo.138.8.5310.
21) Rogers R.S., Graziottin T.M., Lin C.-M. et al. Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-assoicated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats. Int J Impot Res. 2003;15(1):26-37. DOI: 10.1038/sj.ijir.3900943.
22) Traish A.M., Munarriz R., O’Connell L. et al. Effects of medical and surgical castration on erectile function in an animal model. J Androl. 2003;24(3):381-7. DOI: 10.1002/j.1939-4640.2003.tb02686.x.
23) Traish A.M., Toselli P., Jeong S.J., Kim N.N. Adipocyte accumulation in penile corpus cavernosum of the orchiectomized rabbit: a potential mechanism for veno-occlusive dysfunction in androgen deficiency. J Androl. 2005;26(2):242-8. DOI: 10.1002/j.1939-4640.2005.tb01091.x.
24) Rosen R.C., Wu F., Behre H.M. et al. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME). J Sex Med. 2017;14(9):1104-1115. DOI: 10.1016/j.jsxm.2017.07.004.
25) Smith J.B., Rosen J., Colbert A. Low Serum Testosterone in Outpatient Psychiatry Clinics: Addressing Challenges to the Screening and Treatment of Hypogonadism. Sex Med Rev. 2018;6(1):69-76. DOI: 10.1016/j.sxmr.2017.08.007.
26) Bhasin S., Seidman S., Travison T.G. et al. Depressive Syndromes in Men With Hypogonadism in the TRAVERSE Trial: Response to Testosterone-Replacement Therapy. J Clin Endocrinol Metab. 2024;109(7):1814-1826. DOI: 10.1210/clinem/dgae026.
27) Walther A., Breidenstein J., Miller R. Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2019;76(1):31-40. DOI: 10.1001/jamapsychiatry.2018.2734.
28) Corona G., Guaraldi F., Rastrelli G. et al. Testosterone Deficiency and Risk of Cognitive Disorders in Aging Males. World J Mens Health. 2021;39(1):9-18. DOI: 10.5534/wjmh.200017. Epub 2020 Apr 1.
29) Morley J.E., Perry H.M. 3rd. Androgen deficiency in aging men. Med Clin North Am. 1999;83(5):1279-89. DOI: 10.1016/s0025-7125(05)70163-2.
30) Isidori A.M., Balercia G., Calogero A.E. et al. Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology. J Endocrinol Invest. 2015;38(1):103-12. DOI: 10.1007/s40618-014-0155-9.
31) Traish A.M. Testosterone and weight loss: the evidence. Curr Opin Endocrinol Diabetes Obes. 2014;21(5):313-22. DOI: 10.1097/MED.0000000000000086.
32) Saad F., Yassin A., Doros G., Haider A. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I–III: observational data from two registry studies. Int J Obes (Lond). 2016;40(1):162-70. DOI: 10.1038/ijo.2015.139.
33) Steeves J.A., Fitzhugh E.C., Bradwin G. et al. Cross-sectional association between physical activity and serum testosterone levels in US men: results from NHANES 1999-2004. Andrology. 2016;4(3):465-72. DOI: 10.1111/andr.12169.
34) Lee T.W., Kao P.Y., Chen Y.C., Wang S.T. Effects of Testosterone Replacement Therapy on Muscle Strength in Older Men with Low to Low-Normal Testosterone Levels: A Systematic Review and Meta-Analysis. Gerontology. 2023;69(10):1157-1166. DOI: 10.1159/000532062.
35) Rozhivanov R.V., Chernova M.O., Mel’nichenko G.A. et al. The incidence and aggravating factors of male hypogonadism in type 2 diabetes. Diabetes mellitus. 2022;25(4):338-346. Russian (Роживанов Р.В., Чернова М.О., Мельниченко Г.А. и соавт. Частота встречаемости и отягощающие факторы синдрома гипогонадизма у мужчин с сахарным диабетом типа 2. Сахарный диабет. 2022;25(4):338-346). DOI: 10.14341/DM12913).
36) Corona G., Rastrelli G., Vignozzi L. et al. The Role of testosterone treatment in patients with metabolic disorders. Expert Rev Clin Pharmacol. 2021;14(9):1091-1103. DOI: 10.1080/17512433.2021.1938548.
37) Haider K.S., Haider A., Saad F. et al. Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry study. Diabetes Obes Metab. 2020;22(11):2055-2068. DOI: 10.1111/dom.14122.
38) Rochira V., Antonio L., Vanderschueren D. EAA clinical guideline on management of bone health in the andrological outpatient clinic. Andrology. 2018;6(2):272-285. DOI: 10.1111/andr.12470.
39) Isidori A.M., Giannetta E., Greco E.A. et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005;63(3):280-93. DOI: 10.1111/j.1365-2265.2005.02339.x.
40) Corona G., Vena W., Pizzocaro A., et al. Testosterone supplementation and bone parameters: a systematic review and meta analysis study. J Endocrinol Invest. 2022;45(5):911-926. DOI: 10.1007/s40618-021-01702-5.
41) Letkiewicz S., Pilis K., Ślęzak A., et al. Eight Days of Water-Only Fasting Promotes Favorable Changes in the Functioning of the Urogenital System of Middle-Aged Healthy Men. Nutrients. 2020;13(1):113. DOI: 10.3390/nu13010113.
42) Engeler D., Baranowsky A.P., Elneil S. et al. Guideline on chronic pelvic pain syndrome. European Association of Urology. 2012;132 р.
43) Zubkov A.Yu., Antonov N.A. Chronic bacterial prostatitis associated with androgen deficiency. Kazan Medical Journal. 2020;101(3): 389–393. Russian (Зубков А.Ю., Антонов Н.А. Хронический бактериальный простатит, ассоциированный с андрогенным дефицитом. Казанский медицинский журнал. 2020;101(3): 389–393.) DOI: 10.17816/KMJ2020-389).
44) Weinberg J.M. Lipotoxicity. Kidney Int. 2006;70(9):1560-6. DOI: 10.1038/sj.ki.5001834.
45) Lee M.J., Fried S.K. Integration of hormonal and nutrient signals that regulateleptin synthesis and secretion. Am J Physiol Endocrinol Metab. 2009;296(6):E1230-8. DOI: 10.1152/ajpendo.90927.2008.
46) Arnol’di E.K. Chronic prostatitis: problems, expe rience, prospects. Rostov n/D: Feniks, 1999, 14 p. Russian. (Арнольди Э.К. Хронический простатит: проблемы, опыт, перспективы. Ростов-на-Дону: Феникс, 1999, 14 c).
47) Shcheplev P.A., Strachunskiy L.S., Rafal’skiy V.V. et al. Prostatitis. M.: MEDPress-Inform, 2011, 224р. Russian. (Щеплев П.А., Страчунский Л.С., Рафальский В.В. и др. Простатит. М.:МЕДПресс-Информ, 2011, 224с.).
48) Kogan M.I., Ibishev Kh.S., Chernyy A.A., Ferzauli A.Kh. Clinical characteristics of chronic bacterial prostatitis associated with testosterone deficiency. Medical Bulletin of Bashkortostan. 2013;8(2):91–94. Russian. (Коган М.И., Ибишев Х.С., Чёрный А.А., Ферзаули А.Х. Клиническая характеристика хронического бактериального простатита на фоне дефицита тестостерона. Медицинский вестник Башкортостана. 2013;8(2):91–94).
49) Kogan M.I., Avadieva N.E., Gevorkyan L.S. et al. The results of the multicenter prospective comparative study of Androgel in men with endogenous testosterone deficiency and lower urinary tract symptoms, associated with benign prostate hyperplasia (POTOK)]. Urologiia. 2023;(2):32-40. Russian. DOI: 10.18565/urology.2023.2.32-40
50) Nieschlag E. Current topics in testosterone replacement of hypogonadal men. Best Pract Res Clin Endocrinol Metab. 2015;29(1):77-90. DOI: 10.1016/j.beem.2014.09.008.
51) World Health Organization. Guidelines for the use of androgens in men. In WHO Special Programme of Research, Development and Research Training in Human Reproduction & Workshop Conference on Androgen Therapy: Biologic and Clinical Consequences (1990). Marco Island, FL. 1992.
52) Аndrogen replacement therapy market analysis. https://www.coherentmarketinsights.com/market-insight/androgen-replacement-therapy-market-3787.
53) Shoskes J.J., Wilson M.K., Spinner M.L. Pharmacology of testosterone replacement therapy preparations. Transl Androl Urol. 2016;5(6):834-843. DOI: 10.21037/tau.2016.07.10.
54) Rastrelli G., Maggi M., Corona G. Pharmacological management of late-onset hypogonadism. Expert Rev Clin Pharmacol. 2018;11(4):439-458. DOI: 10.1080/17512433.2018.1445969.
55) Wang C., Berman N., Longstreth J.A. et al. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. J Clin Endocrinol Metab. 2000;85(3):964-9. DOI: 10.1210/jcem.85.3.6437.
56) Swerdloff R.S., Wang C., Cunningham G. et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85(12):4500-10. DOI: 10.1210/jcem.85.12.7045.
57) Wang C., Cunningham G., Dobs A. et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89(5):2085-98. DOI: 10.1210/jc.2003-032006.
58) Steidle C., Schwartz S., Jacoby K. et al. North American AA2500 T Gel Study Group. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab. 2003;88(6):2673-81. DOI: 10.1210/jc.2002-021058.
59) Behre H.M., Wang C., Handelsman D.J., Nieschlag E. Pharmacology of testosterone preparations. In E Nieschlag, HM Behre, eds. Testosterone. Action, Deficiency, Substitution, 3rd ed. Cambridge, UK: Cambridge University Press. 2004:405-444.
60) Alves J.V., da Costa R.M., Pereira C.A. et al. Supraphysiological Levels of Testosterone Induce Vascular Dysfunction via Activation of the NLRP3 Inflammasome. Front Immunol. 2020;11:1647. DOI: 10.3389/fimmu.2020.01647.
61) Mackey M.A., Conway A.J., Handelsman D.J. Tolerability of intramuscular injections of testosterone ester in oil vehicle. Hum Reprod. 1995;10(4):862-5. DOI: 10.1093/oxfordjournals.humrep.a136051.
62) Nankin H.R. Hormone kinetics after intramuscular testosterone cypionate. Fertil Steril. 1987;47(6):1004-9.
63) Snyder P.J., Lawrence D.A. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab. 1980;51(6):1335-9. DOI: 10.1210/jcem-51-6-1335.
64) Rhoden E.L., Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350(5):482-92. DOI: 10.1056/NEJMra022251.
65) Ohlander S.J., Varghese B., Pastuszak A.W. Erythrocytosis Following Testosterone Therapy. Sex Med Rev. 2018;6(1):77-85. DOI: 10.1016/j.sxmr.2017.04.001.
66) Bhasin S., Brito J.P., Cunningham G.R. et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. DOI: 10.1210/jc.2018-00229.
67) Wang C., Harnett M., Dobs A.S., Swerdloff R.S. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial. J Androl. 2010;31(5):457-65. DOI: 10.2164/jandrol.109.009597.
68) Nieschlag E., Büchter D., Von Eckardstein S. et al. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin Endocrinol (Oxf). 1999;51(6):757-63. DOI: 10.1046/j.1365-2265.1999.00881.x.
69) Corona G., Maseroli E., Maggi M. Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opin Pharmacother. 2014;15(13):1903-26. DOI: 10.1517/14656566.2014.944896.
70) Hackett G., Cole N., Saghir A., et al. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU Int. 2016;118(5):804-813. DOI: 10.1111/bju.13516.
71) Zitzmann M., Cremers J.F., Krallmann C. et al. The HEAT-Registry (HEmatopoietic Affection by Testosterone): comparison of a transdermal gel vs long-acting intramuscular testosterone undecanoate in hypogonadal men. Aging Male. 2022;25(1):134-144. DOI: 10.1080/13685538.2022.2063830.
72) Lopez D.S., Advani S., Tsilidis K.K. et al. Endogenous and exogenous testosterone and prostate cancer: decreased-, increased- or null-risk? Transl Androl Urol. 2017;6(3):566-579. DOI: 10.21037/tau.2017.05.35.
73) Debruyne F.M., Behre H.M., Roehrborn C.G. et al. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men. BJU Int. 2017;119(2):216-224. DOI: 10.1111/bju.13578.
74) Boyle P., Koechlin A., Bota M. et al. Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis. BJU Int. 2016;118(5):731-741. DOI: 10.1111/bju.13417.
75) Haider A., Zitzmann M., Doros G. et al. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median follow up of 3 registries. J Urol. 2015;193(1):80-6. DOI: 10.1016/j.juro.2014.06.071.
76) Wallis C.J., Lo K., Lee Y. et al. Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. Lancet Diabetes Endocrinol. 2016;4(6):498-506. DOI: 10.1016/S2213-8587(16)00112-1.
77) Bhasin S., Travison T.G., Pencina K.M. et al. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Netw Open. 2023;6(12):e2348692. DOI: 10.1001/jamanetworkopen.2023.48692.
78) Fernández-Balsells M.M., Murad M.H., Lane M. et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560-75. DOI: 10.1210/jc.2009-2575.
79) Guo C., Gu W., Liu M. et al. Efficacy and safety of testosterone replacement therapy in men with hypogonadism: A meta-analysis study of placebo-controlled trials. Exp Ther Med. 2016;11(3):853-863. DOI: 10.3892/etm.2015.2957.
80) Permpongkosol S., Khupulsup K., Leelaphiwat S. et al. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism. J Sex Med. 2016;13(8):1199-211. DOI: 10.1016/j.jsxm.2016.06.003.
81) Vigen R., O’Donnell C.I., Barón A.E. et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829-36. DOI: 10.1001/jama.2013.280386.
82) Traish A.M., Guay A.T., Morgentaler A. Death by testosterone? We think not! J Sex Med. 2014 Mar;11(3):624-9. DOI: 10.1111/jsm.12464.
83) Shores M.M., Smith N.L., Forsberg C.W. et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97(6):2050-8. DOI: 10.1210/jc.2011-2591.
84) Muraleedharan V., Marsh H., Kapoor D. et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169(6):725-33. DOI: 10.1530/EJE-13-0321.
85) Laughlin G.A., Barrett-Connor E., Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93(1):68-75. DOI: 10.1210/jc.2007-1792.
86) Corona G. et al. Endogenous Testosterone Levels and Cardiovascular Risk: Meta-Analysis of Observational Studies. J Sex Med. 2018;15(9):1260-1271. DOI: 10.1016/j.jsxm.2018.06.012.
87) Jones T.H., Arver S., Behre H.M. et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34(4):828-37. DOI: 10.2337/dc10-1233.
88) Wittert G., Bracken K., Robledo K.P. et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 2021;9(1):32-45. DOI: 10.1016/S2213-8587(20)30367-3.
89) Lincoff A.M., Bhasin S., Flevaris P. et al. TRAVERSE Study Investigators. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117. DOI: 10.1056/NEJMoa2215025.
90) Corona G., Dicuio M., Rastrelli G. et al. Testosterone treatment and cardiovascular and venous thromboembolism risk: what is ‘new’? J Investig Med. 2017;65(6):964-973. DOI: 10.1136/jim-2017-000411.
91) Ayele H.T., Brunetti V.C., Renoux C. et al. Testosterone replacement therapy and the risk of venous thromboembolism: A systematic review and meta-analysis of randomized controlled trials. Thromb Res. 2021;199:123-131. DOI: 10.1016/j.thromres.2020.12.029.
92) Rastrelli G., Dicuio M., Reismann Y. et al. Cardiovascular impact of testosterone therapy for hypogonadism. Expert Rev Cardiovasc Ther. 2018;16(9):617-625. DOI: 10.1080/14779072.2018.1510314.
93) Corona G., Rastrelli G., Monami M. et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013;168(6):829-43. DOI: 10.1530/EJE-12-0955.
Об авторах / Для корреспонденции
А в т о р д л я с в я з и: П. И. Раснер – д.м.н., профессор, главный врач Научно-образовательного института клинической медицины им. Н.А. Семашко ФГБОУ ВО «Российский университет медицины», Москва, Россия; e-mail: dr.rasner@gmail.com
Похожие статьи
